

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 68661

**Title:** Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

**Reviewer's code:** 06099578

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** United Kingdom

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-06-15

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-06-20 23:59

**Reviewer performed review:** 2021-06-21 10:18

**Review time:** 10 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

General comments Esophageal cancer is one of the most common forms of cancer, and the preferred treatment modality for esophageal cancer is surgery. However, most of patients are no longer eligible for radical surgery upon diagnosis. So, RCT remains the mainstay of treatment for locally advanced esophageal cancer, the treatment modalities have long been controversial. In this manuscript, authors conducted the present prospective study to investigate the efficacy and safety of induction chemotherapy with ABP plus lobaplatin followed by concurrent RCT in the treatment of locally advanced esophageal cancer. After two cycles of induction chemotherapy with ABP combined with lobaplatin and concurrent radio chemotherapy was given after the induction chemotherapy. Finally, they concluded induction chemotherapy with ABP plus lobaplatin followed by concurrent RCT is effective in patients with locally advanced ESCC, with mild adverse effects. The paper is written well, the Introduction give a good overview about the study background. The aim of the study is fulfilled and the material studied allows to draw the conclusions. The Results are presented clearly and have been discussed well. Specific comments 1. Units of time should be mo, wk, and d instead of month, week, and day. 2. In table 2, it would be better to give the full name of “ORR, PR, SD, PD”. 3. Add the number of patients with the AE in table 3. 4. The format of references should be modified.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 68661

**Title:** Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

**Reviewer's code:** 06099629

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-06-15

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-06-21 00:00

**Reviewer performed review:** 2021-06-21 10:19

**Review time:** 10 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

The efficacy of induction chemotherapy followed by definitive RCT in treating esophageal cancer has been proved in recent years. Maohui Yan et al. demonstrated that induction chemotherapy with ABP plus lobaplatin followed by concurrent RCT is effective in patients with locally advanced ESCC, with mild adverse effects. This is a very interesting study. And the manuscript is well written. The introduction part is detailed and comprehensive, involving a lot of background knowledge, and citing a lot of literature to introduce the research status of the treatment of locally advanced esophageal cancer. In addition, the manuscript also introduces the limitations of the research and the direction of follow-up research. I really thank for a useful and important synopsis of this important topic. I only have a small question. At present, congratulations on your phase II study results are surprising and exciting, so do you need to do phase III clinical trials to verify its accuracy in the follow-up?

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 68661

**Title:** Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

**Reviewer's code:** 06099609

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Indonesia

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-06-15

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-06-21 00:00

**Reviewer performed review:** 2021-06-22 09:34

**Review time:** 1 Day and 9 Hours

<b>Scientific quality</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

Several clinical trials have explored and evaluated the multidisciplinary treatments for advanced unresectable esophageal cancer, however, there is still no standardized treatment protocol. This prospective study enrolled 29 patients with locally advanced ESCC between April 2019 and October 2020. Their cox multivariate analysis of the efficacy and prognosis concluded that 2 cycles of induction chemotherapy followed by concurrent RCT significantly reduced the risk of disease progression compared with 2 cycles of chemotherapy only, suggesting that induction chemotherapy combined with definitive RCT is an efficacious and well-tolerated treatment modality in patients with esophageal cancer. With fewer and milder toxicities, it enhances chemotherapy tolerability and prolongs survival. Very interesting study. And the manuscript is well written. In my opinion, this protocol is worthy of clinical promotion and application. The experiment of the study is designed very well. Thank you for giving opportunity to review the study. I recommend accepting this manuscript for publication after a minor language polishing.